The Differential Effects of Diabetes Therapy on Inflammation

NCT02150707 · Completed

Last updated 2026-05-28

This clinical trial is testing how different diabetes treatments affect inflammation in people with type 2 diabetes and kidney disease.

Status Completed The study has finished.

Type Observational

Participants 17 people

Who can join Ages 30+ · all sexes

Timeline Started 2014-05 · est. completion 2015-12

Where 1 site · Ireland

What this study is testing ClinicalTrials.gov NCT02150707 ↗

Description as written by the study sponsor.

This study aims to determine if different diabetes treatments have different effects on inflammation; in particular, kidney inflammation. This type of inflammation is common in people with diabetes, and can lead to kidney failure. This study will investigate the effect of different types of diabetes treatment on kidney inflammation. This will help us to decide if certain types of medicine should be preferred in people with evidence of inflammation in their kidneys, as this may help prevent major complications including kidney failure.

Treatments tested

Dipeptidyl-Peptidase IV Inhibitors also known as DPP4 inhibitors Drug

Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
Glucagon-Like Peptide 1 also known as Liraglutide, Exenatide Drug

Glucagon-Like Peptide 1 to treat hyperglycaemia

Main thing measured	Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio
Sponsor	University College Dublin
Conditions studied	Diabetic Nephropathy, Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02150707 ↗